Neurol. praxi. 2021;22(4):338-342 | DOI: 10.36290/neu.2021.055

Fycompa in children - posibilities of use and practical experience

MUDr. Michal Ryzí, Ph.D., MUDr. Pavlína Danhofer, Ph.D., MUDr. Michaela Habalová, doc. MUDr. Hana Ošlejšková, Ph.D.
Klinika dětské neurologie LF MU a FN Brno
Centrum pro epilepsie Brno

Approved options of antiepileptic treatment in children are limited in comparison with adults and the process of introduction of new antiepileptic drug is often longer. The aim of this review is to present comprehensive information concerning perampanel, its new indications and practical experience. Fycompa® (perampanel - PER) is antiepileptic drug with a specific mechanism of action low interactive potential, safe and well tolerated, with satisfactory long term tolerability profile. When rightly use it can be usable add-on therapy in early phase of treatment.

Keywords: epilepsy, treatment, perampanel, indication in children.

Accepted: August 9, 2021; Prepublished online: August 9, 2021; Published: September 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ryzí M, Danhofer P, Habalová M, Ošlejšková H. Fycompa in children - posibilities of use and practical experience. Neurol. praxi. 2021;22(4):338-342. doi: 10.36290/neu.2021.055.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arzimanoglou A, Kalilani L, Anamoo MA, Cooney M, Golembesky A, Taeter C, Bozorg A. Tofighy A, Wheless J. Role of observational studies in supporting extrapolation of efficacy data from adults to children with epilepsy - A systematic review of the literature using lacosamide as an example. Eur J Paediatr Neurol 2019; 23: 589-603. Go to original source... Go to PubMed...
    2. Biró A, Stephani U, Tarallo T, Bast T, Schlachter K, Fleger M, Kurlemann G, Fiedler B, Leiz S, Nikanorova M, Wolff M, Müller A, Selch C, Staudt M, Kluger G. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics 2015; 46(2): 110-116. Go to original source... Go to PubMed...
    3. Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015; 17(2): 117-123. Go to original source... Go to PubMed...
    4. Danhofer P, Habalová M. Perampanel v dětské epileptologii - naše zkušenosti. 54. eesko-slovenské dny dětské neurologie. Sborník abstrakt. 2021.
    5. Datta AN, Xu Q, Sachedina S, Boelman C, Huh L, Connolly MB. Clinical Experience With Perampanel for Refractory Pediatric Epilepsy in One Canadian Center. Journal of Child Neurology 2017; 32(9): 834-839. Go to original source... Go to PubMed...
    6. De Liso P, Vigevano F, Specchio N, De Palma L, Bonanni P, Osanni E, Coppola G, Parisi P, Grosso S, Verrotti A, Spalice A, Nicita F, Zamponi N, Siliquini S, Giordano L, Martelli P, Guerrini R, Rosati A, Ilvento L, Belcastro V, Striano P, Vari MS, Capovilla G, Beccaria F, Bruni O, Luchetti A, Gobbi G, Russo A, Pruna D, Tozzi AE, Cusmai R. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study. Epilepsy Res 2016 127: 93-100. Go to original source... Go to PubMed...
    7. Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med 2012; 172(10): 781-788. Go to original source... Go to PubMed...
    8. Fogarasi A, Flamini R, Milh M, Phillips S, Yoshitomi S, Patten A, Takase T, Laurenza A, Ngo LY. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to
    9. Franco V, Canevini MP, Capovilla G, De Sarro G, Galimberti CA, Gatti G, Guerrini R, La Neve A, Rosati E, Specchio LM, Striano S, Tinuper P, Perucca E. Off-Label Prescribing of Antiepileptic Drugs in Pharmacoresistant Epilepsy: A Cross-Sectional Drug Utilization Study of Tertiary Care Centers in Italy. CNS Drugs 2014; 28: 939-949. Go to original source... Go to PubMed...
    10. Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011; 52: 1331-1340. Go to original source... Go to PubMed...
    11. Heyman E, Lahat E, Levin N, Epstein O, Lazinger M, Berkovitch M, Gandelman-Marton R. Tolerability and efficacy of perampanel in children with refractory epilepsy. Dev Med Child Neurol 2017; 59(4): 441-444. Go to original source... Go to PubMed...
    12. Kwan P, Brodie MJ, Laurenza A, FitzGibbon H, Gidal BE. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: impact of mechanism of action and pharmacokinetics on clinical outcomes. Epilepsy research 2015; 117: 117-124. Go to original source... Go to PubMed...
    13. Lin KL, Lin JJ, Chou ML, Hung PC, Hsieh MY, Chou IJ, Lim SN, Wu T, Wang HS. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics. Epilepsy Behav 2018; 85: 188-194. Go to original source... Go to PubMed...
    14. Pellock JM, Arzimanoglou A, D'Cruz O, Holmes GL, Nordli D, Shinnar S, Pediatric Epilepsy Academic Consortium for Extrapolation. Extrapolating evidence of antiepileptic drug efficacy in adults to children ≥2 years of age with focal seizures: The case for disease similarity Epilepsia. 2017; 58(10): 1686-1696. Go to original source... Go to PubMed...
    15. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166(9): 1021-1026. Go to original source... Go to PubMed...
    16. Rektor I, Krauss GL, Inoue Y, Kaneko S, WIlliams B, Patten A,Bibbiani F, Laurenza A, Wechsler RT. Long-term efficacy and safety of adjunctive perampanel in open-label extension (OLEx) studies: post hoc analysis. Epilepsia 2017; 58: S110-S110.
    17. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents 2011; 11(2): 56-63. Go to original source... Go to PubMed...
    18. Swiderska N, Tan HJ, Rajai A, Silwal A, Desurkar A, Martland T. Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: A UK national multicentre study. Seizure 2017; 52: 63-70. Go to original source... Go to PubMed...
    19. Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, Squillacote D, Yang H, Zhu J, Laurenza A. Effi cacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013; 54(8): 1481-1489. Go to original source... Go to PubMed...
    20. Templeton D. Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist. Epilepsia 2009; 50(Suppl. 11): abstract 1.199. Go to PubMed...
    21. Thijs RD, Surges R, O'Brien TJ, Sander JW. Epilepsy in adults. Lancet 2019; 393(10172): 689-701. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.